21
2024-04
GT20029 China Phase II Trial For AGA Reached Primary Endpoint
April 21, 2024-Kintor Pharma announced that GT20029 China Phase II Trial For AGA Reached Primary Endpoint.
02
2024-04
AACR 2024 Foreight | Three Oncology Studies From Kintor Pharma Selected
Three oncology studies from kintor pharma selected 2024 American Association of Cancer Research Annual Meeting.
13
2024-03
c-Myc Degrader Study Published in Subsidiary Journal of Nature
c-Myc Degrader Study Published in Subsidiary Journal of Nature. The study shows that c-Myc molecular glue compound has great potential.
28
2023-10
Suzhou, October 28, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the results of the Phase Ib/II clinical trial of ALK-1 antibody GT90001 combined with PD-1 antibody nivolumab in the treatment of advanced hepatocellular carcinoma (HCC) were published online by the well-known journal BMC Medicine (Impact factor: 11.806). The results showed that this combination regimen is well-tolerated and has promising anti-tumor activity in patients with recurrent advanced HCC, with a confirmed overall response rate (ORR) of 30% and a remarkable long-tail effect.
11
2023-10
Suzhou, October 11, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that its Hedgehog/SMO inhibitor GT1708F had obtained conditional approval to conduct Phase II clinical trial in China by the National Medical Products Administration (NMPA) for treatment of idiopathic pulmonary fibrosis (IPF).
28
2023-08
Kintor Pharma Announces 2023 Interim Results and Recent Business Highlights
Suzhou, August 28, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma” or “the company”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced its 2023 interim results and released an update on its recent business highlights.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn